Frank Phillips

Frank Phillips

Auto-generated profile, based on publicly available information

Frank Phillips

NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and the University of Nottingham

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 September 2021 in Journal of Crohn's and Colitis
Verified
Journal Article
Closed access
PDF file
FPFrank Phillips
Frank Phillips
BVBram Verstockt
Bram Verstockt
MSMalgorzata Sladek
Malgorzata Sladek
NBNanne de Boer
Nanne de Boer
KKKonstantinos Katsanos
Konstantinos Katsanos
PEPierre Ellul
Pierre Ellul
Background: Orofacial granulomatosis [OFG] is a rare syndrome that may be associated with Crohn’s disease [CD]. We aimed to characterise this relationship and the management options in the biologic era.Methods: This multicentre case series was supported by the European Crohn’s and Colitis Organisation [ECCO], and performed as part of the Collaborative Network of Exceptionally Rare case reports [CONFER] project. Clinical data were recorded in a standardised collection form.Results: This report includes 28 patients with OFG associated with CD: 14 males (mean age of 32 years, ±12.4 standard deviation [SD]) and 14 females [40.3 years, ±21.0 SD]. Non-oral upper gastrointestinal tract involvement was seen in six cases and perianal disease in 11. The diagnosis of OFG was made before CD diagnosis in two patients, concurrently in eight, and after CD diagnosis in 18. The distribution of OFG involved the lips in 16 cases and buccal mucosa in 18. Pain was present in 25 cases, with impaired swallowing or speaking in six. Remission was achieved in 23 patients, notably with the use of anti-tumour necrosis factors [TNFs] in nine patients, vedolizumab in one, ustekinumab in one, and thalidomide in two. A further five cases were resistant to therapies including anti-TNFs.Conclusions: OFG associated with CD may occur before, concurrently with, or after the diagnosis of CD. Perianal and upper gastrointestinal [UGI] disease are common associations and there is a significant symptom burden in many. Remission can be obtained with a variety of immunosuppressive treatments, including several biologics approved for CD.

11 September 2021 in Journal of Crohn's and Colitis
Verified
Journal Article
Closed access
PDF file
FPFrank Phillips
Frank Phillips
BVBram Verstockt
Bram Verstockt
Davide Giuseppe RibaldoneDavide Giuseppe Ribaldone
Davide Giuseppe Ribaldone
IGIvan Guerra
Ivan Guerra
NTNiels Teich
Niels Teich
SSShaji Sebastian
Shaji Sebastian
Background: There is a small but measurable increased risk of lymphoma in inflammatory bowel disease [IBD], with a suggestion that primary intestinal lymphoma [PIL] in IBD is associated with inflamed tissue and immunosuppressant use, mainly thiopurines. Methods: This multicentre case series was supported by the European Crohn’s and Colitis Organisation [ECCO] and performed as part of the Collaborative Network of Exceptionally Rare case reports [CONFER] project. Clinical data were recorded in a standardized case report form. Results: Fifteen patients with intestinal lymphoma from eight centres were included (12 males, 11 patients with Crohn’s disease [CD], mean age 47.8 [±16.4 SD, range 26–76] years at lymphoma diagnosis). Lymphoma type was diffuse large B-cell lymphoma [DLBCL] in eight, Hodgkin’s disease in two, mucosa-associated lymphoid tissue [MALT] lymphoma in three, and single cases of immunoblastic lymphoma and indolent T-cell lymphoma. Lymphoma was located within the IBD-affected area in ten patients. At lymphoma diagnosis, nine patients had a history of azathioprine or anti-tumour necrosis factor [TNF] use. Lymphoma was diagnosed at a mean time of 10.4 [±7.07, 1–24] years after IBD diagnosis in 11 patients, prior to IBD in two and concurrently in two. Sustained remission over a median follow-up time of 6.5 [1.5–20] years was achieved in ten patients after treatment; five of them had started biological therapy [including anti-TNFs, vedolizumab and ustekinumab] for active CD subsequent to their PIL treatment. Conclusion: In this small case series, two-thirds of patients developed lymphoma in the IBD-affected area, and almost two-thirds had a history of thiopurine or anti-TNF use. Biologics were restarted without recurrence of lymphoma in half of the remitters.

2 November 2022 in Journal of Crohn's and Colitis
Verified
Journal Article
Closed access
PDF file
PEPierre Ellul
Pierre Ellul
JSJohn Schembri
John Schembri
ABAndrea Vella Baldacchino
Andrea Vella Baldacchino
TMTamás Molnár
Tamás Molnár
TRTamas Resal
Tamas Resal
YSY Snir
Y Snir
Post-inflammatory polyps (PIPs) are considered as indicators of previous episodes of severe inflammation and mucosal ulceration. Inflammatory bowel disease (IBD), namely Crohn’s disease (CD) and ulcerative colitis (UC), exhibit a perpetuating, relapsing, and remitting pattern and PIPs is a frequent sequela of chronicity. The aim of this study was to determine whether a high PIPs burden is associated with a more severe disease course in patients with IBD. This was a multinational, multicentre, retrospective study. IBD patients previously diagnosed with PIPs were retrieved from the endoscopic database of each centre. PIPs burden was evaluated and associated with demographic and clinical data as well as factors indicating a more unfavorable disease course. A total of 504 IBD patients with PIPs were recruited (male: 61.9%). The mean age at IBD diagnosis was 36.9 (±16.8) years. Most patients (74.8%) were diagnosed with UC. A high PIPs burden was present in 53.4% of patients. On multivariable Cox regression analysis, high PIPs burden was independently associated with treatment escalation (HR 1.35, 95% CI 1.04-1.75; P=0.024), hospitalization (HR 1.90; 95% CI 1.24 – 2.90; P=0.003), need for surgery (HR 2.28; 95% CI 1.17-4.44, P=0.02) and younger age at diagnosis (HR 0.99, 95% CI 0.98–0,99; p=0.003). PIPs burden was associated with a more severe outcome. Future prospective studies should focus on the characterisation of PIPs burden as to further risk stratify this patient cohort.

20 April 2021 in medRxiv
Verified
Preprint
Open access
PDF file
FPFrank Phillips
Frank Phillips
JCJane Crowley
Jane Crowley
SWSamantha Warburton
Samantha Warburton
GGGeorge S.D. Gordon
George S.D. Gordon
APAdolfo Parra-Blanco
Adolfo Parra-Blanco
Background and Aims: Aerosol generating procedures have become an important healthcare issue due to the COVID-19 pandemic, as the SARS-CoV-2 virus can be transmitted via aerosols. We aimed to characterise aerosol and droplet generation in gastrointestinal endoscopy, where there is little evidence. Methods: This prospective observational study included patients undergoing routine per-oral gastroscopy (POG, n=36), trans-nasal endoscopy (TNE, n=11) and lower gastrointestinal (LGI) endoscopy (n=48). Particle counters took measurements near the appropriate orifice (two models used, diameter ranges 0.3μm-25μm and 20μm-3000μm). Quantitative analysis was performed by recording specific events and subtracting the background particles. Results: POG produced 1.96x the level of background particles (p<0.001) and TNE produced 2.00x (p<0.001) but a direct comparison shows POG produces 2.00x more particles than TNE. LGI procedures produce significant particle counts (p<0.001) with 2.4x greater production per procedure than POG but only 0.63x production per minute. Events significant relative to the room background particle count were: POG-throat spray (150.0x, p<0.001), oesophageal extubation (37.5x, p<0.001), coughing/gagging (25.8x, p<0.01); TNE-nasal spray (40.1x, p<0.001), nasal extubation (32.0x, p<0.01), coughing/gagging (20.0, p<0.01); LGI-rectal intubation (9.9x, p <0.05), rectal extubation (27.2x, p <0.01), application of abdominal pressure (9.6x, p <0.05), rectal insufflation/retroflexion (7.7x, p <0.01). These all produced particle counts larger than or comparable to volitional cough. Conclusion: Gastrointestinal endoscopy performed via the mouth, nose or rectum all generates significant quantities of aerosols and droplets. As the infectivity of procedures is not established, we therefore suggest adequate PPE is used for all GI endoscopy where there is a high population prevalence of COVID-19. Avoiding throat and nasal spray would significantly reduce particles generated from UGI procedures.

24 August 2022 in medRxiv
Verified
Preprint
Open access
PDF file
FPFrank Phillips
Frank Phillips
JCJane Crowley
Jane Crowley
SWSamantha Warburton
Samantha Warburton
KSKarren Staniforth
Karren Staniforth
APAdolfo Parra-Blanco
Adolfo Parra-Blanco
GGGeorge S.D. Gordon
George S.D. Gordon
Objectives Upper GI endoscopies are aerosol generating procedures (AGPs), increasing risk of spreading airborne pathogens. We aim to quantify mitigation of airborne particles via improved ventilation, specifically laminar flow theatres and portable HEPA filters, during and after upper GI endoscopies. Methods This observational study included patients undergoing routine oral gastroscopy in a standard endoscopy room with 15-17 air changes per hour, a standard endoscopy room with portable HEPA filtration unit, and a laminar flow theatre with 300 air changes per hour. A particle counter (diameter range 0.3μm-25μm) took measurements 10cm from the mouth. Three analyses were performed: whole procedure particle counts, event-based counts and air clearance estimation using post-procedure counts. Results Compared to a standard endoscopy room, for whole procedures we observe a 28.5x reduction in particle counts in laminar flow (p5μm for oral extubation (12.2x,p<0.01), reduction in particles <5μm for coughing/gagging (6.9x, p<0.05) and reduction for all sizes in anaesthetic throat spray (8.4x,p<0.01) but no significant effect of HEPA filtration. However, we find that in the fallow period between procedures HEPA filtration reduces particle clearance times by 40%. Conclusions Laminar flow theatres are highly effective at dispersing aerosols immediately after production and should be considered for high-risk cases where patients are actively infectious or supply of PPE is limited. Portable HEPA filers can safely reduce fallow time between procedures by 40%.

6 December 2022 in medRxiv
Verified
Preprint
Open access
PDF file
FPFrank Phillips
Frank Phillips
JCJane Crowley
Jane Crowley
SWSamantha Warburton
Samantha Warburton
GGGeorge S.D. Gordon
George S.D. Gordon
APAdolfo Parra-Blanco
Adolfo Parra-Blanco
Digestive endoscopy has been proven to produce aerosols (1–3). This represents a risk of infection by COVID-19 and other airborne viruses. A number of protective barriers have been proposed to minimise that risk. Continuous suction of the oral cavity (1), shielding barriers (4,5), masks (6,7), and increasing the distance between patient and endoscopist (8) have been proposed as methods to reduce the exposure of endoscopists and endoscopy staff to aerosols. Here, we present a study that uses modified bronchoscopy masks (Explorer endoscopy facemask, Intersurgical Ltd., United Kingdom) to attenuate aerosol production at the patient’s mouth (bare mask shown in Fig. 1a and in use during an upper GI endoscopy in Fig. 1b). We find that this approach offers 47% (p=0.01) reduction in particle count for particles <5μm in diameter (i.e. aerosols), which are known to spread SARS-CoV-2.